Oncoloxía médica
Servizo
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (101)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
-
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
-
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology
Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
-
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology
2023
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925
-
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Scientific Reports
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)
Clinical and Translational Oncology
-
Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section
Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958
-
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e166-e174